Literature DB >> 9262535

Salmeterol in the treatment of chronic asthma.

G E D'Alonzo1, K A Tolep.   

Abstract

Salmeterol is a highly selective beta 2-adrenoreceptor agonist with a long duration of action--as long as 12 hours or more. When inhaled twice daily in the management of chronic asthma, salmeterol can improve lung function and the quality of life for patients with asthma, and reduce acute asthma exacerbations. It is also a useful adjunct in the treatment of exercise-induced asthma and nocturnal asthma. In patients who continue to have symptomatic asthma despite the regular use of an inhaled corticosteroid, salmeterol acts as a secondary controller of symptoms and reduces the need for inhaled short-acting beta 2-agonist "rescues". Since salmeterol is different from other beta 2 agonists, patients must be carefully educated in its proper use. Salmeterol should be administered in combination with an inhaled anti-inflammatory medication as adjunctive therapy, but it should not be used for rescue bronchodilatation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9262535

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  4 in total

Review 1.  Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma.

Authors:  Francine M Ducharme; Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 2.  Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children.

Authors:  Francine M Ducharme; Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2010-05-12

Review 3.  Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children.

Authors:  Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

Review 4.  Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD).

Authors:  Hilla Mills; Ronald Acquah; Nova Tang; Luke Cheung; Susanne Klenk; Ronald Glassen; Magali Pirson; Alain Albert; Duong Trinh Hoang; Thang Nguyen Van
Journal:  Emerg Med Int       Date:  2022-07-18       Impact factor: 1.621

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.